Subscribe

Anemia-Related Costs and Adverse Event Rates in Cancer Patients Who Do Not Respond to Erythropoietin Stimulating Agents

VBCC - March 2013, Volume 4, No 3 - AVBCC 2013 3rd Annual Conference Abstracts
Allicia Girvan
Gerhardt Pohl
Yiu-Keung Lau
Pamela Landsman-Blumberg
Nianwen Shi
Helen Varker
Paul Juneau
Lee Bowman

Background: While broadly utilized for treatment of anemia in cancer patients, treatment with erythropoietin stimulating agents (ESA) is not recommended in patients who fail to respond within 6-8 weeks.

Objective: This study examined the rate of adverse events (AE) and costs of continued exposure to ESAs in the absence of clinical response compared to those responding to ESA treatment.

Methods: Electronic medical records of breast, head & neck, cervical, non-small cell lung cancer, and multiple myeloma patients initiating ESAs during 1/1/2007 - 7/1/2011 were extracted (ACORN, Memphis, TN). Patients with ESA use ≥8 weeks, valid Hemoglobin (Hb) values ≤28 days before and 43-70 days after ESA start were retained. Following the ASCO/ASH guidelines, “responders” had Hb increase ≥1 g/dL from start to between days 43 to 70. Non-responders were then divided into “continuing” or “discontinuing” based on presence of ESA treatment after the 43-70 day window. Days on ESA, anemia-related costs (ESA, laboratory, visits), and AE rates were analyzed. ESA costs were estimated by 2011 Wholesale Acquisition Cost (WAC) dose billed and other anemia-related costs by applying Current Procedural Terminology (CPT) pay proxies, derived from the 2011 MarketScan Databases.

Results: Compared to responders, continuing non-responders had significantly longer mean ESA treatment (+17 days; P = 0.023) and significantly higher median anemia-related costs (+$3,385; P <.001) during post-response period and for entire ESA treatment period (+$2,927; P <.001). Discontinuing non-responders incurred significantly lower median anemia-related costs than responders during ESA treatment (–$2,368; P <.001). Additionally, continuing non-responders experienced a higher number of AEs compared to discontinuing non-responders (9.4% vs 3.4%, respectively).

Table
Table
View larger version

Conclusion: For every one non-responding cancer patient who discontinued treatment according to recommendations, there were three non-responders who continued treatment. The treatment duration for non-responding patients who continued ESAs was longer even than for those responding to ESA treatment. Treatment costs were significantly higher for non-responders continuing ESA treatment than the other two cohorts. It was not clear from these data whether the increased AE rate in non-responders who continued ESAs, compared to those who discontinued, was offset by other positive outcomes for the patients.

Related Items
Low Incidence of Treatment-Induced Peripheral Neuropathy (PN) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM) Treated with Single-Agent Carfilzomib
Thomas Martin, Ravi Vij, Ashraf Z. Badros, Leanne McCulloch, Sundar Jagannath University of California-San Francisco, San Francisco, CA, USA; Washington University School of Medicine, St. Louis, MO, USA; Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA; Onyx Pharmaceuticals, South San Francis
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Effects of 5-Hydroxytryptamine-3 Receptor Antagonists (5-HT3 RAs) in Lung Cancer Patients with Multiple Risk Factors
Claudio Faria, Russell Knoth, Annette Powers. Eisai, Inc. Woodcliff Lake, NJ 07677
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients Receiving 5-HT3-RA Therapy throughout Chemotherapy Cycles
Faria C, Nagl N, Powers A. Eisai, Inc. 100 Tice Blvd. Woodcliff Lake, NJ 07667
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
An Assessment of Racial Differences in Toxicities and Supportive Care in Patients with Metastatic Breast Cancer (MBC)
George Dranitsaris, Nancy Beegle, Traci Kalberer, Zhixiao Wang, Claudio Faria, Sibel Blau
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Impact of Treatment Modification on Treatment Duration in Metastatic Breast Cancer Patients Treated with Eribulin Mesylate
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Impact of Granulocyte Colony-Stimulating Factor and Treatment Modification on Eribulin Mesylate Therapy in Metastatic Breast Cancer Patients with Neutropenia
Gluck S, Yardley D, Belk K, Craver C, Cox D, Faria C, University of Miami, Leonard M. Miller School of Medicine, Miami, FL; Tennessee Oncology, PLLC, Nashville, TN; MedAssets, Inc., Charlotte, NC; Eisai Inc., Woodcliff Lake, NJ
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Say Ahh! Making Sense of Oral Assessments for Mucositis
Joanne Growney, MA, RN, ANP-BC, OCN, Rebecca Martin, BSN, RN, OCN, Phyllis McKiernan, RN, MSN, APN-BC, Joan Collela, RN, DNP, APN-BC, NP-C, Claudia Douglas, RN, MA, CNN, APN-C
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Wait Time and Patient Satisfaction—Improving Outcomes Can Be as Easy as Child’s Play
Julia Whiteker, Ann Bredensteiner
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Imatinib Can Still Be Used as 1st-Line for Treating Chronic Myelogenous Leukemia
Wesley Wong, PhD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Cost Analysis of Bortezomib Retreatment Compared with Switching to Carfilzomib in Patients with Relapsed Multiple Myeloma Previously Treated with Bortezomib
Kevin B. Knopf, MD, MPH, Marie-Hélène Lafeuille, MA, Jonathan Gravel, MS, Patrick Lefebvre, MA, Liviu Niculescu, MD, Abbie Ba-Mancini, MBA, Esprit Ma, MPH, Mei Sheng Duh, MPH, ScD
VBCC - March 2013, Volume 4, No 3 published on April 1, 2013 in AVBCC 2013 3rd Annual Conference Abstracts
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology